Search results for "Biliary tract neoplasm"

showing 10 items of 13 documents

Multifocal Biliary Cystadenocarcinoma of the Liver: CT and Pathological Findings

2006

Biliary cystadenocarcinoma is a rare tumor that originates from the hepatobiliary epithelium. Although this tumor can affect any portion of the biliary tree, intrahepatic location is more common. It is usually a slow growing tumor and often asymptomatic until it reaches a considerable size. The lesion is most often solitary and large when discovered; multiple lesions or metastases within the liver are very rare. A 63-year-old man was referred to our institute for weight loss, abdominal discomfort, worsening bulky symptoms in the right upper abdominal quadrant, and an increase in serum aminotransferases that had been present for several months. Spiral CT of the abdomen demonstrated two lesi…

MaleCancer ResearchPathologymedicine.medical_specialtyBiliary CystadenocarcinomaBiopsyCystadenocarcinoma030218 nuclear medicine & medical imagingLiver ct03 medical and health sciences0302 clinical medicineHumansMedicineCystadenocarcinomaTransaminasesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseEpitheliumBiliary Tract Surgical ProceduresRare tumorBiliary Tract Neoplasmsmedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisLaparoscopyRadiologybusinessTomography Spiral ComputedTumori Journal
researchProduct

A New Self-Expanding Nitinol Stent (JoStent SelfX) for Palliation of Malignant Biliary Obstruction: a Pilot Study

2004

Background and Study Aims: The JoStent SelfX is a new biliary uncovered self-expanding nitinol stent. The main advantage of this stent in comparison with the gold standard Wallstent is the minimal shortening (< 10%) that occurs during stent deployment. A prospective feasibility study was conducted to evaluate the method of stent implantation and the stent's short-term efficacy. Patients and Methods: Between April 2001 and December 2002, the JoStent SelfX was implanted in 20 patients with inoperable malignant biliary obstructions, mainly caused by pancreatic cancer (12 of 20). All patients underwent sphincterotomy prior to stent insertion. After implantation, laboratory parameters for choles…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentPilot ProjectsPostoperative ComplicationsMulticenter trialAlloysHumansMedicinecardiovascular diseasesBiliary sludgeAgedAged 80 and overBiliary tract neoplasmbusiness.industryPalliative CareGastroenterologyStentMiddle Agedequipment and suppliesmedicine.diseaseSurgeryBiliary Tract Surgical ProceduresStenosisBiliary Tract NeoplasmsTreatment Outcomesurgical procedures operativeBiliary tractFemaleStentsRadiologyBiliary Tract Surgical ProceduresbusinessEndoscopy
researchProduct

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

2011

&lt;i&gt;Background:&lt;/i&gt; This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients. &lt;i&gt;Methods:&lt;/i&gt; Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and measurable disease were enrolled. Treatment consisted of FDR gemcitabine at 800 mg/m&lt;sup&gt;2&lt;/sup&gt; on days 1 and 8 every 21 days with capecitabine administered orally b.i.d. in equal doses (650 mg/m&lt;sup&gt;2&lt;/sup&gt; b.i.d.) for 14 days (28 doses). &lt;i&gt;…

OncologyMaleCancer Researchmedicine.medical_specialtyDisease free survivalSettore MED/06 - Oncologia MedicaDeoxycytidineDisease-Free SurvivalCapecitabineBiliary tract cancer; Capecitabine; Fixed-dose rate; GemcitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisCapecitabineAgedNeoplasm StagingBiliary tract cancerFixed-dose ratebusiness.industryGeneral MedicineFixed dose rateMiddle AgedGemcitabineGemcitabineClinical trialBiliary Tract NeoplasmsOncologyBiliary tract cancerNeoplasm stagingFemaleFluorouracilbusinessmedicine.drug
researchProduct

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)

2009

Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were…

Oncologymedicine.medical_specialtyPathologyCancer ResearchAntimetabolites Antineoplasticmedicine.medical_treatmentEquilibrative nucleoside transporter 1DeoxycytidineEquilibrative Nucleoside Transporter 1Statistical significanceInternal medicineDrug DiscoveryMedicineHumansHENT1PharmacologyChemotherapyUnivariate analysisPredictive markerBiliary tract cancer; Gemcitabine; HENT1; Predictive factor; Drug Discovery3003 Pharmaceutical Science; Pharmacology; Cancer Researchbiologybusiness.industryDrug Discovery3003 Pharmaceutical ScienceCancermedicine.diseaseImmunohistochemistryGemcitabineGemcitabineBiliary Tract NeoplasmsOncologybiology.proteinImmunohistochemistryBiliary tract cancerbusinessPredictive factormedicine.drug
researchProduct

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker…

2017

Abstract Background Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), ov…

MaleOncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier Estimatemedicine.disease_causeDeoxycytidine0302 clinical medicineRisk FactorsGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicinePrecision MedicineAged 80 and overPanitumumabAntibodies MonoclonalCombination chemotherapyMiddle AgedIsocitrate DehydrogenaseBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)Female030211 gastroenterology & hepatologyKRASmedicine.drugAdultmedicine.medical_specialtyAdolescentDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Young Adult03 medical and health sciencesInternal medicineBiomarkers TumorHumansPanitumumabAgedCisplatinChemotherapybusiness.industryGene Expression ProfilingGemcitabineGemcitabineClinical trialMutationCisplatinbusinessEuropean Journal of Cancer
researchProduct

Presence of white bile in malignant biliary obstruction is associated with poor prognosis: personal preliminary observations

2006

OBJECTIVE: The chemical composition and clinical significance of white bile in patients with malignant obstructive jaundice were evaluated in a prospective study. MATERIALS AND METHODS: 115 consecutive patients with inoperable malignant biliary obstruction underwent endoscopic placement of 10 Fr straight, plastic biliary stents, Amsterdam-type. Bile was aspirated during the endoscopic procedure and a blood sample was taken. Patients were divided into two groups: those with white bile and those with yellow bile. The groups were compared for decremental fall in bilirubin, cholangitis after stent insertion, and survival. RESULTS: Thirty-five patients (15 men, 20 women; mean age 54 years) under…

Malemedicine.medical_specialtyBilirubinmedicine.drug_classColordigestive systemGastroenterologyBile Acids and Saltschemistry.chemical_compoundInternal medicineBileHumansMedicineClinical significanceProspective StudiesProspective cohort studyAgedProportional Hazards ModelsCholestasisBile acidbusiness.industryBile ductBilirubinMiddle AgedJaundiceAlkaline PhosphatasePrognosisPancreatic NeoplasmsBiliary Tract Neoplasmsmedicine.anatomical_structurechemistryCardiothoracic surgeryFemaleGallbladder NeoplasmsStentsSurgerymedicine.symptombusinessAbdominal surgery
researchProduct

Risk estimation for biliary tract cancer: Development and validation of a prognostic score.

2017

Background & Aims Biliary tract cancer is a rare tumour entity characterized by a poor prognosis. We aimed to identify prognostic factors and create a prognostic score to estimate survival. Methods Clinical data of the training set, consisting of 569 patients treated from 2000 to 2010 at Hannover Medical School, were analysed. A prognostic model defining three prognostic risk groups was derived from Cox regression analyses. The score was applied and validated in an independent cohort of 557 patients from four different German centres. Results Median overall survival (OS) was 14.5 months. If complete resection was performed, the patients had a significantly improved OS (23.9 months; n=242) a…

OncologyMalemedicine.medical_specialtyRisk AssessmentPrognostic scoreMetastasisCholangiocarcinomaCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineGermanymedicineHumansAgedBiliary tract neoplasmBiliary tract cancerHepatologybusiness.industryProportional hazards modelMiddle Agedmedicine.diseasePrognosisSurgeryBiliary Tract Neoplasms030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleRisk assessmentbusinessCohort studyLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Trends in the incidence and management of biliary tract cancer: a French population-based study.

2011

The trends in incidence and management of biliary tract cancer (BTC) were investigated in a well-defined French population over a 30-year period (1976-2005).Data were obtained from the Burgundy digestive cancer registry. Age-standardised incidence rates and trends in incidence were determined. Treatment and stage at diagnosis were also investigated. Five-year survival rates were calculated.Six hundred and fifteen cases of BTC were recorded. There was no significant change in BTC incidence over the 30-year period. For extrahepatic BTC age-standardised incidence rates were 1.1/100,000 for 1976-80 and 2001-2005. These rates were respectively 0.3 and 0.2/100,000 for intrahepatic BTC. The propor…

Malemedicine.medical_specialtyTime FactorsPopulationGastroenterologyBile duct cancerInternal medicineEpidemiologymedicineHumanseducationSurvival rateAgedNeoplasm Stagingeducation.field_of_studyBiliary tract cancerHepatologyRelative survivalbusiness.industryIncidence (epidemiology)Incidencemedicine.diseasePopulation based studySurvival RateBiliary Tract NeoplasmsFemaleFrancebusinessJournal of hepatology
researchProduct

Bactibilia in women affected with diseases of the biliary tract and pancreas. A STROBE guidelines-adherent cross-sectional study in Southern Italy.

2018

Abstract Purpose. Bile is a hepatobiliary lipid-rich sterile solution, and its colonization by microorganisms defines the condition of bactibilia. In this study, we aimed to assess the bile microbiological flora and its potential link with comorbidity in women. Methodology. We performed a microbiologic investigation on 53 female patients with biliopancreatic diseases who granted consent, and we analysed the data using a MATLAB platform. Results. We found that the most frequent disease associated with bactibilia was pancreas head carcinoma (PHC) (P=0.0015), while the least frequent disease was gall bladder carcinoma (GBC) (P=0.0002). The most common microorganisms were Pseudomonas spp. (P&lt…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyPancreatic diseaseMediterranean dietCross-sectional studyMicrobiologyGastroenterologyBiliary disease03 medical and health sciences0302 clinical medicineInternal medicineGram-Negative BacteriamedicineCarcinomaBileHumansBiliary TractAgedAged 80 and overbusiness.industryMortality rateGeneral MedicineMiddle Agedmedicine.diseaseComorbidityBactibiliaPancreatic Neoplasms030104 developmental biologyBiliary Tract NeoplasmsCross-Sectional StudiesItalyBiliary tract030220 oncology & carcinogenesisFemalebusinessJournal of medical microbiology
researchProduct